1,1,1-三丁基-N,N-二甲基锡烷胺 | 1067-24-9

• 分子结构分类: 有机化合物 - 有机金属化合物 - 有机过渡后金属化合物
• 中文名称: 1,1,1-三丁基-N,N-二甲基锡烷胺
• 英文名称: dimethylamino tributyltin
• 英文别名: Dimethylamino-tri-n-butyl-stannan；Dimethylamino-tributylstannan；dimethylazanide;tributylstannanylium
• CAS: 1067-24-9
• 化学式: C₁₄H₃₃NSn
• mdl: MFCD00077998
• 分子量: 334.133
• InChiKey: OWTXIZLJXVEGMT-UHFFFAOYSA-N

物化性质

• 熔点：
  <0°C
• 沸点：
  86°C 0,1mm
• 密度：
  1,08 g/cm3
• 闪点：
  115°C

计算性质

• 辛醇/水分配系数(LogP)：
  3.68
• 重原子数：
  16
• 可旋转键数：
  10
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

安全信息

• TSCA：
  No
• 海关编码：
  2931900090
• 危险品运输编号：
  UN 1760

反应信息

• 作为反应物：
  描述：

  1,1,1-三丁基-N,N-二甲基锡烷胺 生成 三正丁基溴化锡
  参考文献：
  名称：

  Gmelin Handbuch der Anorganischen Chemie, Gmelin Handbook: Sn: Org.Comp.12, 1.4.1.1.1.5.2.1.1, page 38 - 56

  摘要：

  DOI：
• 作为产物：
  描述：

  N,N-二甲基三甲基硅胺 、 三正丁基甲氧基锡 生成 1,1,1-三丁基-N,N-二甲基锡烷胺
  参考文献：
  名称：

  Armitage, D. A.; Sinden, A. W., Journal of Organometallic Chemistry

  摘要：

  DOI：

文献信息

• Amino derivatives of metals and metalloids
  作者：K. Jones、M.F. Lappert

  DOI：10.1016/s0022-328x(00)84649-5

  日期：1965.4

  (Dialkylamino)trialkylstannanes, R3Sn-NR′2, are very reactive reagents. With protic species HA, including hydrogen chloride, water, alcohols, ammonia and primary and secondary amines, diphenylphosphine, diphenylarsine, acetylene and monosubstituted acetylenes, cyclopentadiene and indene, they readily eliminate amine R′2NH and afford organotin products of formula R3Sn-A. Nitriles and nitro-compounds

  （二烷基氨基）trialkylstannanes，R 3的Sn-NR' 2，非常活泼的试剂。与质子物种HA，包括氯化氢，水，醇，氨以及伯胺和仲胺，二苯基膦，diphenylarsine，乙炔和单取代炔，环戊二烯和茚，它们容易消除胺R' 2 NH和得到有机锡式R的产品3的Sn -一种。人们认为，具有α-氢原子的腈和硝基化合物与丙酮在第一步中的行为相似，但副反应也很重要。
• [EN] PYRIDONE ANALOGS USEFUL AS MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS<br/>[FR] ANALOGUES DE PYRIDONE UTILES COMME ANTAGONISTES DU RÉCEPTEUR 1 DE L'HORMONE CONCENTRANT LA MÉLANINE
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2010104830A1

  公开（公告）日：2010-09-16

  MCHR1 antagonists are provided having the following Formula I: wherein A1 and A2 are independently C or N; E is C or N; D1 is a bond, -CR8R9X-, -XCR8R9-, -CHR8CHR9-, -CR10=CR10'-, -C≡C-, or 1,2-cyclopropyl; X is O, S or -NR11; R1, R2, and R3 are independently selected from the group consisting of hydrogen, halogen, lower alkyl, lower cycloalkyl, lower cycloalkoxy, -CF3, -OCF3, -OR12 and -SR12; G is O or S; D2 is lower alkyl, lower cycloalkyl, lower alkylcycloalkyl, lower cycloalkylalkyl, lower cycloalkoxyalkyl or lower alkycycloalkoxy; Z1 and Z2 are independently hydrogen, halogen, lower alkyl, lower cycloalkyl, lower alkoxy, lower cycloalkoxy, halo, -CF3, -OCONR14R14', -CN, -CONR14R14', -SOR12, -SO2R12, -NR14COR14', -NR14CO2R14', -CO2R12, NR14SO2R12 or -COR12 provided that if Z1 is -CH3 and one of R1, R2, or R3 is F, then Z2 cannot be H;; R5, R6, and R7 are independently selected from the group consisting of hydrogen, halogen, lower alkyl, lower cycloalkyl, -CF3, -SR12, lower alkoxy, lower cycloalkoxy, -OCH2OMe, -CN, -CONR14R14', SOR12, SO2R12, NR14COR14', NR14CO2R12, CO2R12, NR14SO2R12 and -COR12; R8, R9, R10, R10', R11 are independently hydrogen or lower alkyl; R12 is lower alkyl or lower cycloalkyl; and R14 and R14' are independently H, lower alkyl, lower cycloalkyl or R14 and R14' together with the N to which they are attached form a ring having 4 to 7 atoms. Such compounds are useful for the treatment of MCHR1 mediated diseases, such as obesity, diabetes, IBD, depression, and anxiety.

  MCHR1拮抗剂具有以下的化学式I：其中A1和A2独立地为C或N；E为C或N；D1为键，-CR8R9X-，-XCR8R9-，-CHR8CHR9-，-CR10=CR10'-，-C≡C-，或1,2-环丙基；X为O，S或-NR11；R1、R2和R3独立地选自氢、卤素、低烷基、低环烷基、低环氧基、-CF3、-OCF3、-OR12和-SR12的组；G为O或S；D2为低烷基、低环烷基、低烷基环烷基、低环烷基烷基、低环氧基烷基或低烷基环氧基；Z1和Z2独立地为氢、卤素、低烷基、低环烷基、低烷氧基、低环氧基、卤、-CF3、-OCONR14R14'、-CN、-CONR14R14'、-SOR12、-SO2R12、-NR14COR14'、-NR14CO2R14'、-CO2R12、NR14SO2R12或-COR12，但如果Z1为-CH3且R1、R2或R3中有一个为F，则Z2不能为H；R5、R6和R7独立地选自氢、卤素、低烷基、低环烷基、-CF3、-SR12、低烷氧基、低环氧基、-OCH2OMe、-CN、-CONR14R14'、SOR12、SO2R12、NR14COR14'、NR14CO2R12、CO2R12、NR14SO2R12和-COR12；R8、R9、R10、R10'、R11独立地为氢或低烷基；R12为低烷基或低环烷基；R14和R14'独立地为H、低烷基、低环烷基或R14和R14'与它们连接的N一起形成具有4至7个原子的环。这类化合物对于治疗MCHR1介导的疾病，如肥胖症、糖尿病、炎症性肠病、抑郁症和焦虑症是有用的。
• Indane modulators of glucocorticoid receptor, AP-1, and/or NF/kB activity and use thereof
  申请人：Duan Jingwu

  公开号：US20070185056A1

  公开（公告）日：2007-08-09

  Novel non-steroidal compounds are provided that are useful in treating diseases associated with modulation of the glucocorticoid receptor, AP-1, and/or NF-κB activity including obesity, diabetes, inflammatory and immune diseases having the structure of formula (I): or enantiomers, diastereomers, or a pharmaceutically-acceptable salt, or hydrate, thereof, where X is -A 1 QA 2 -; Q is a bond, —C(═O)—, —OC(O)—, —C(═O)NR 5 —, —SO p —, —SO p NR 5 —, —C(O)O—, —NR 5 C(O)—, —OC(O)NR 5 —, —NR 5 C(O)O—, —S(O) p NR 5 C(O)—, —C(O)NR 5 S(O) p — —NR 5 S(O) p —, or —NR 5 C(═O)NR 6 —. Y is selected from hydrogen, C 1-4 alkyl, OR 16 , substituted C 1-6 alkyl, cycloalkyl, aryl, heterocyclo and heteroaryl. A 1 and A 2 are independently selected from a bond, C 1-3 alkylene, or C 1-3 alkenylene, and R 1 -R 11 are defined herein. Also provided are pharmaceutical compositions, combinations, and methods of treating obesity, diabetes and inflammatory- or immune-associated diseases comprising said compounds.

  提供了一种新型的非甾体化合物，可用于治疗与糖皮质激素受体、AP-1和/或NF-κB活性调节相关的疾病，包括肥胖、糖尿病、炎症性和免疫性疾病，其具有以下结构的化学式（I）： 或其对映体、非对映体、药用可接受的盐或水合物，其中X为-A 1 QA 2 -；Q为键，—C(═O)—，—OC(O)—，—C(═O)NR 5 —，—SO p —，—SO p NR 5 —，—C(O)O—，—NR 5 C(O)—，—OC(O)NR 5 —，—NR 5 C(O)O—，—S(O) p NR 5 C(O)—，—C(O)NR 5 S(O) p —，—NR 5 S(O) p —，或—NR 5 C(═O)NR 6 —。Y从氢、C 1-4 烷基、OR 16 、取代的C 1-6 烷基、环烷基、芳基、杂环烷基和杂芳基中选择。A 1 和A 2 独立选择自键、C 1-3 烷基或C 1-3 烯基，R 1 -R 11 在此定义。还提供了包含所述化合物的药物组合物、组合物和治疗肥胖、糖尿病和炎症性或免疫相关疾病的方法。
• Substituted Heterocyclic Ethers and Their Use in CNS Disorders
  申请人：Degnan Andrew P.

  公开号：US20090018132A1

  公开（公告）日：2009-01-15

  The invention encompasses compounds of Formula I, including pharmaceutically acceptable salts, their pharmaceutical compositions, and their use in treating CNS disorders.

  这项发明涵盖了公式I的化合物，包括药用盐、它们的药物组合物以及它们在治疗中枢神经系统疾病中的用途。
• Influences on the Relative Rates for C−N Bond-Forming Reductive Elimination and β-Hydrogen Elimination of Amides. A Case Study on the Origins of Competing Reduction in the Palladium-Catalyzed Amination of Aryl Halides
  作者：John F. Hartwig、Steven Richards、David Barañano、Frédéric Paul

  DOI：10.1021/ja954121o

  日期：1996.1.1

  elimination is the palladium-catalyzed amination of aryl bromides to give arylamines. The primary side products formed in these catalytic aminations are arenes, the products of aryl halide reduction. It would seem reasonable that both arylamine and arene products result from competitive reductive elimination of amine and β-hydrogen elimination from a common amido aryl intermediate. Our results do substantiate

  β-氢消除的典型分解限制了晚期过渡金属酰胺络合物的生产催化有机金属化学。然而，一种已被证明涉及具有 β-氢的后金属酰氨基络合物并避免广泛的 β-氢消除的反应是钯催化的芳基溴化物胺化生成芳基胺。在这些催化胺化反应中形成的主要副产物是芳烃，即芳基卤化物还原的产物。芳胺和芳烃产物都是由胺的竞争性还原消除和常见的酰胺芳基中间体的 β-氢消除产生的，这似乎是合理的。我们的结果确实证实了涉及酰胺基的竞争性β-氢消除和还原消除，但也揭示了使用 Pd(II) 前体时发生的第二种还原途径。芳基卤化物还原的第二种途径主要通过以下观察结果显示：（1）芳基卤化物配合物的化学计量反应...